Key result
Post-VAD sustained kidney function improvement fails to reduce 1-year mortality despite baseline CKD risks.
Why the study?
Although VAD implantation improves kidney function, whether this improvement is sustained or associated with improved clinical outcomes remained unclear.
Does sustained improvement in kidney function after ventricular assist device implantation reduce the risk of thromboembolism, hemorrhage, or all-cause mortality in patients with end-stage heart failure?
Cohort (n=228)
No
Does sustained improvement in kidney function after ventricular assist device implantation reduce the risk of thromboembolism, hemorrhage, or all-cause mortality in patients with end-stage heart failure?
Although VAD implantation produces sustained 1-year improvement in CKD stage for most patients (especially younger recipients and those with eGFR ≥15), post-implant mortality is driven by baseline kidney dysfunction (CKD stages 3b-5) rather than subsequent renal recovery.
Answers are grounded in this paper and cite their sources.
Baseline CKD stage 3b-5 was associated with higher post-VAD mortality independent of renal recovery; leaves open effects on thromboembolism or hemorrhage.
Although heart transplantation remains the gold standard for management of heart failure, ventricular assist devices (VAD) have emerged as viable alternatives. VAD implantation improves kidney function. However, whether the improvement is sustained or associated with improved outcomes is unclear. Herein we assess kidney function improvement, predictors of improvement, and associations with thromboembolism, hemorrhage, and mortality in VAD patients. Kidney function was defined using chronic kidney disease (CKD) stages: stage 1 (glomerular filtration rate [eGFR] ≥ 90 ml/min/1.73 m), stage 2 (eGFR 60-90 ml/min/1.73 m), stage 3a (eGFR 45-59 ml/min/1.73 m), stage 3b (eGFR 30-44 ml/min/1.73 m), stage 4 (eGFR 15-30 ml/min/1.73 m), and stage 5 (eGFR < 15 ml/min/1.73 m). Improvement in kidney function was defined as an improvement in eGFR that resulted in a CKD stage change to one of lesser severity. Kidney function improved post implant, and was maintained over 1 year for all patients, except those with baseline stage 5 CKD. Younger age at implantation (OR 0.93, 95% CI: 0.90-0.96, P < 0.0001) was associated with sustained improvement in kidney function. Poor kidney function was associated increased mortality but not with thromboembolism or hemorrhage. Compared to patients with baseline eGFR > 45 ml/min/1.73 m; patients with eGFR < 45 ml/min/1.73 m had a higher mortality risk (HR 3.32, 95% CI: 1.10-9.98, p = 0.03 for stage 3b; HR 4.07, 95% CI: 1.27-13.1, p = 0.02 for stage 4; and HR 4.01, 95% CI: 1.17-13.7, p = 0.03 for stage 5 CKD). Kidney function was not associated with thromboembolism or hemorrhage, and sustained improvement was not associated with lower risk of death. However, poor kidney function at implantation was associated with an increased risk of mortality.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2019) conducted a cohort in End-stage heart failure undergoing ventricular assist device (VAD) implantation (n=228). Sustained improvement in kidney function (CKD stage improvement over 1 year) and baseline CKD stage post-VAD implantation vs. No sustained improvement in kidney function / baseline CKD Stage 1 or eGFR >45 ml/min/1.73 m2 was evaluated on All-cause mortality at 1 year by sustained kidney function improvement (HR 1.03, 95% CI 0.58-1.84, p=0.91). Sustained kidney function improvement after VAD implantation did not reduce 1-year mortality, whereas baseline CKD stage 3b-5 increased mortality risk.
Synapse has enriched 10 related papers. Consider them for comparative context: